Raytheon awarded $71 million in Navy contracts for missile systems
89bio, Inc. (NASDAQ:ETNB) Chief Technical Operations Officer Le-Nguyen Quoc, sold 10,461 shares of common stock on July 15, 2025, for approximately $115,280. The transaction comes amid the stock’s impressive 68.78% surge over the past six months, with InvestingPro data showing the company’s market capitalization now stands at $1.56 billion. The shares were sold at prices ranging from $10.855 to $11.17.
The transaction was executed under a Rule 10b5-1 trading plan adopted on July 1, 2024. Following the transaction, Le-Nguyen directly owns 309,364 shares of 89bio, Inc. common stock. Le-Nguyen also indirectly owns 14,216 shares by spouse. According to InvestingPro analysis, the stock currently appears slightly undervalued, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US equities.
In other recent news, 89bio Inc . held its 2025 Annual Meeting of Stockholders, where all proposed agenda items were approved. This included the election of directors Martin Babler, Derek DiRocco, Ph.D., and Lota Zoth, C.P.A., who secured their positions on the board with strong support. Additionally, the appointment of KPMG LLP as the company’s independent auditor was ratified. In another development, Cantor Fitzgerald adjusted its financial outlook for 89bio, lowering the stock target to $55 from $58 while maintaining an Overweight rating. This adjustment followed the release of 89bio’s first-quarter 2025 earnings. The firm expressed continued confidence in the potential of 89bio’s lead product candidate, pegozafermin, especially in its ongoing Phase 3 trials for MASH. 89bio is also progressing with several key trials, with significant milestones expected in the coming years. The company’s research and development efforts aim to address unmet medical needs in serious lipid and liver diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.